|
HS Code |
471820 |
| Chemical Name | 3-((1S)-1-(Dimethylaminoethyl))Phenol |
| Molecular Formula | C10H15NO |
| Molecular Weight | 165.23 g/mol |
| Cas Number | 4224-67-1 |
| Appearance | White to off-white crystalline powder |
| Melting Point | 91-94°C |
| Solubility | Soluble in water and organic solvents |
| Purity | Typically ≥98% |
| Storage Conditions | Store at 2-8°C, in a tightly sealed container |
| Smiles | CN(C)CC(C1=CC(=CC=C1)O) |
| Synonyms | 3-(Dimethylamino-1-ethyl)phenol |
| Inchi | InChI=1S/C10H15NO/c1-11(2)7-10(8-4-3-5-9(10)12)6-8/h3-5,12H,6-7H2,1-2H3 |
As an accredited 3-((1S)-1-(Dimethylaminoethyl))Phenol factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Amber glass bottle containing 100 grams of 3-((1S)-1-(Dimethylaminoethyl))phenol, with tamper-evident cap and hazard labeling. |
| Shipping | Shipping of 3-((1S)-1-(Dimethylaminoethyl))phenol requires secure, leak-proof packaging to prevent exposure. It should be transported in compliance with relevant chemical safety regulations, including labeling as a potentially hazardous, irritant material. Ensure temperature control if needed and include all documentation, such as Safety Data Sheets, for safe and authorized handling during transit. |
| Storage | 3-((1S)-1-(Dimethylaminoethyl))phenol should be stored in a tightly closed container, in a cool, dry, and well-ventilated area, away from heat, ignition sources, and incompatible substances such as strong oxidizers and acids. Protect from light and moisture. Use appropriate chemical-resistant storage materials, and ensure the area is clearly labeled and access is restricted to trained personnel. |
Competitive 3-((1S)-1-(Dimethylaminoethyl))Phenol prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615380400285 or mail to sales2@liwei-chem.com.
We will respond to you as soon as possible.
Tel: +8615380400285
Email: sales2@liwei-chem.com
Flexible payment, competitive price, premium service - Inquire now!
As a chemical manufacturer who has watched the steady evolution of pharmaceutical intermediates, I have a front-row seat to the demands, hurdles, and rewards that follow innovation in our field. The product 3-((1S)-1-(Dimethylaminoethyl))phenol has become an active topic among medicinal chemists and industry formulators looking for potent synthetic building blocks. Instead of taking a broad or generic approach, we share insights grounded in hands-on production experience and ongoing engagement with researchers who seek consistent quality and tailored functionality.
3-((1S)-1-(Dimethylaminoethyl))phenol flows through our lines as more than a formula in a database. Each batch draws from a tightly screened selection of feedstocks, ensuring that the chiral center is preserved and reflected in the enantiomeric excess. The (1S)-configuration matters—a detail often lost when the market fills with racemic or uncertain mixtures. Our technicians constantly calibrate their process equipment and double-check each fraction, using chiral HPLC and NMR for confirmation. This relentless drive for purity cuts down on synthetic steps downstream and keeps our partners’ research and scale-up plans moving.
Lab users tell us that off-spec material can quickly stall a promising synthesis or create downstream headaches during scale-up. Early on, some clients tried less carefully prepped 3-((1S)-1-(Dimethylaminoethyl))phenol from secondary sources and ran into trouble with color, inconsistent melting points, or residual starting material. We’ve seen how even minor contamination or the wrong optical rotation creates headaches when reactors churn for hours only to yield a product with the wrong activity or purity. That is why our synthesis hinges on control: pressure checks through every reactor run, careful inert atmosphere management, and stepwise extraction protocols for every kilogram we process.
While most datasheets tout an HPLC assay figure, that value only scratches the surface of what defines this intermediate. Our own analytical records typically show purity values exceeding 99% by HPLC, but beyond that number lives a much more relevant story—one that involves residual solvent content below commonly encountered limits, optical purity tracked batch over batch, and real feedback from scale trials. We reinforce our confidence in quality through GC-MS mapping and meticulous documentation so that researchers receive material that genuinely supports advanced synthesis, rather than stalls or complications.
The organic structure of 3-((1S)-1-(Dimethylaminoethyl))phenol attracts skilled medicinal chemists aiming to assemble a variety of active pharmaceutical ingredients (APIs). Many routes toward β-adrenergic agents, anesthetics, and other central nervous system modulators pass through similar intermediates. We have supported a range of custom projects where subtle tweaks in precursor selection or protecting group strategies shift outcomes dramatically. The trimethylamine side chain and the phenol ring system are more than just functional pieces—they guide selectivity during downstream amide coupling, alkylation, and rearrangement chemistry. Researchers working on next-generation molecular scaffolds often use our product for asymmetric synthesis, since the starting enantiopurity greatly influences drug efficacy and safety.
Running a manufacturing facility means always staying tuned to how a product behaves at every stage. In practice, 3-((1S)-1-(Dimethylaminoethyl))phenol presents itself as a fine, off-white crystalline solid, or occasionally as a clear oil when ambient conditions shift. We avoid careless handling that can introduce hydrolysis or oxidation during packaging. Each batch passes air-tight filling and is sealed in amber glass or high-density polyethylene containers designed for both laboratory use and pilot-scale transfer. Given the sensitivity of many synthetic schemes, our packing methods prevent both environmental ingress and cross-contamination, supporting downstream reproducibility with each shipment. Logistics teams further maintain temperature integrity in transit so that stored material arrives with its physical and chemical properties untouched.
The best performing chemical isn’t just about the molecular structure on a label. Day-to-day, teams throughout the production chain review in-process data, carry out repeat impurity profiling on archived lots, and revisit reaction conditions if even minor shifts are noticed. Manufacturing rarely follows a monotone script—at scale, subtle exotherms or solvent-grade shifts can alter product signatures. We stay ahead by keeping archived reference samples so that routine analytical and long-term stability checks are more than a regulatory box-tick: they’re a working part of our improvement cycle. Partnering R&D departments often call to request lot-specific certificates of analysis and secondary analytical support, not as a formality but because their findings in the lab depend as much on our transparency as our base quality. This cycle of collaboration sustains confidence from one synthetic campaign to the next.
Manufacturers always juggle a spread of intermediates for different client needs. In our experience, products like N,N-dimethylamino-functionalized aromatic compounds or other chiral phenol derivatives often pop up as comparative choices for similar downstream pharmaceutical goals. What sets 3-((1S)-1-(Dimethylaminoethyl))phenol apart, especially made in a controlled factory setting, is its very specific stereochemistry and the reliability of its side chain installation. Alternatives without stereospecific synthesis steps often force additional chiral separation work—an extra bottleneck. Our hands-on manufacturing improvements have led to chiral resolutions that consistently sidestep epimerization or racemization, letting the downstream process operate with the same expected yield and selectivity shift after shift.
Some clients used to work with generically named aminophenols or their non-chiral versions. Cost seemed lower at first glance, but the time spent troubleshooting byproducts and adjusting column purifications cut into any hoped-for savings. Those lessons kept our focus sharp: rather than chasing the widest possible portfolio, we put expertise behind a select line of chiral intermediates and hone reproducibility, leaving the variable batches and inconsistent specs for others.
Specifications mean the difference between reliable research and costly do-overs. Our practical specifications draw not from a one-size-fits-all template, but from targeted feedback across the pharmaceutical and discovery chemistry world. Melting point, specific rotation, loss on drying, solvent content, and impurity profile all get fine-tuned batches and batches, not just checked off on a form. If a research group or formulation specialist needs a tighter spec for a pilot run, we review process yield, grain size, and contaminant profile with them directly. These ongoing dialogues matter more than boilerplate specs: chemistry moves fast, and so does our willingness to adjust.
Over the years, we kept track of where clients trip over supply chain issues. Chiral intermediates suffer from lead time problems if outsourcers cut corners or have thin experience with optically active compounds. Lost weeks in the project timeline hurt more than list price differences. We’ve built local redundancy in sourcing, vertical integration for core precursors, and solid relationships with small batch reprocessors. Safe, continuous supply keeps synthetic efforts on-schedule—superior product is worthless if stuck at a border or strangled by paperwork. Staying connected to downstream users and understanding their pipeline flow builds resilience into the very way we schedule production and shipping.
Scale-up brings its own challenges. At the multi-kilo stage, variability that goes unnoticed with small samples becomes crippling. That reality shaped our own manufacturing toolkit: we tune reaction conditions at each new scale, match batch records to process signatures, and always keep archived reference samples to benchmark against. This practical approach sidesteps the surprises that have left other suppliers scrambling and keeps our partners’ timelines predictable.
Researchers in both industry and academic sectors explore new drugs with increasing interest in chiral building blocks. Large pharmaceutical teams use our 3-((1S)-1-(Dimethylaminoethyl))phenol to streamline their syntheses of drug candidates, while university labs apply small samples for new reaction methodologies. Some projects require gram quantities to validate a reaction’s selectivity or mechanism, while others place kilo-size orders to feed preclinical pipelines. Feedback loops from these frontline users let us refine both the physical properties and analytical support offered, keeping the material aligned with the state of the art.
We have observed shifts in usage—projects no longer settle for racemic intermediates unless there’s a deliberate reason. Regulatory scrutiny around chirality in APIs continues to rise, and our plant response tracks with that. At the same time, environmental considerations place increasing importance on atom economy and reducing hazardous side-products. Our teams act on the practical impact of these trends by regularly updating workup and downstream handling protocols and investing in equipment upgrades that limit solvent waste or unnecessary work-up steps. The most effective manufacturing improvement comes not from theory, but from hands-on discovery and a constant ear to customer needs.
Synthetic chemists face enough hurdles as it is—complicated purification steps, risk of racemization, and residual solvent contamination can undo weeks of careful planning. By keeping a manufacturing presence close to where R&D happens, we reduce the risks that come from poorly controlled processes or third-party reselling. We have seen firsthand how variations in phenolic or amine starting material quality throw off both process yield and biological activity in the finished drugs. Our on-site analytical support and in-process controls help minimize such risks at every stage, from raw material screening to the post-synthesis workup and final QC release.
Problems with byproduct management require regular upgrades to filtration and recrystallization steps. Keeping impurities below 0.2% on related substances or residual starting materials is not just an analytical feat—it shapes downstream process safety and predictability. Our manufacturing line adjusts filtration and work-up protocols as soon as any spike in minor contaminants appears, even at trace levels. We’ve learned that ignoring minor process shifts for the sake of expediency only leads to bigger losses later.
No factory can stand still and meet the changing needs of drug discovery. By staying open to detailed feedback, our technical teams log every request—from special packaging requirements to requests for lower moisture content or modified batch sizes. Teams across the plant and the R&D department meet weekly to review both in-house analytical results and direct client input. This two-way interaction leads to iterative improvement, with recorded outcomes from real synthesis projects often shaping the next round of manufacturing adjustments.
A good example comes from a recent project where a group requested a narrow fraction only, targeting a specific melting point range for a large cGMP synthesis campaign. Their trust in our willingness to adapt—rather than dump a generic spec—opened new applications for their projects, and the technical details we shared on process conditions and limitations helped them skip months of revalidation and extra pilot trials.
Streamlining routes through precise intermediates like 3-((1S)-1-(Dimethylaminoethyl))phenol represents not just an incremental improvement, but a bedrock change in the way research groups and manufacturers join forces for effective drug development. We constantly track technical literature and emerging synthetic methods, adjusting our own chemistry and engineering practices to match tomorrow’s demands. Our process engineers modify synthetic routes when new, cleaner options appear, balancing safety, sustainability, and throughput. This readiness to adapt only comes from steady hands-on practice—no theory replaces the lessons learned from daily process tuning and direct user engagement.
From our production floor, the full impact of 3-((1S)-1-(Dimethylaminoethyl))phenol stretches far beyond its molecular structure. It stands as an example of manufacturing grown out of real trial and error, direct feedback, and a commitment to steady improvement. These values support not just individual research teams, but the wider community advancing new medicines, shaping safer, more effective therapies, and pursuing discovery with confidence in every gram they receive.
